How to Track GLP-1 Injection Sites

GLP-1 medications such as Ozempic® (semaglutide), Wegovy® (semaglutide), Mounjaro® (tirzepatide), and Zepbound® (tirzepatide) are injected subcutaneously once per week into the abdomen, thigh, or upper arm. The FDA prescribing information for each of these medications recommends rotating the injection site with every dose to reduce the risk of injection-site reactions and tissue changes. Tracking where you inject each week helps ensure proper rotation and more consistent medication absorption.

Why does injection site rotation matter for GLP-1 medications?

Injecting into the same spot repeatedly can cause local tissue changes over time. The most well-documented complication is lipohypertrophy — a buildup of fatty tissue under the skin that creates visible lumps or firm areas. A 2023 meta-analysis published in Diabetes Research and Clinical Practice estimated the pooled prevalence of lipohypertrophy at approximately 38% among patients who inject subcutaneously, with individual study rates ranging from 11.1% to 73.4%.

While lipohypertrophy has been studied primarily in insulin-treated patients, the underlying mechanism — repeated needle trauma to the same area of subcutaneous tissue — applies to any injectable medication. The Forum for Injection Technique (FIT) guidelines note that although current evidence has not confirmed lipohypertrophy specifically with GLP-1 receptor agonists, other injection-site complications such as redness, swelling, and nodules can occur without proper rotation.

Beyond cosmetic concerns, tissue changes at overused injection sites can impair medication absorption. Injecting into lipohypertrophic tissue has been shown to reduce and delay drug absorption in insulin studies, and the same principle applies to subcutaneous GLP-1 medications. Proper rotation helps maintain consistent drug delivery from week to week.

Where are the approved injection sites for GLP-1 medications?

The FDA prescribing information for semaglutide (Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) identifies three approved injection areas: the abdomen (at least 2 inches away from the navel), the front of the thigh (middle area), and the back of the upper arm. All three sites deliver the medication subcutaneously — just under the skin — and any of them can be used for each dose.

There are small differences in absorption speed between sites. A pharmacokinetic analysis of semaglutide found that bioavailability was approximately 12% lower when injecting in the thigh compared with the abdomen. However, this difference is not considered clinically significant by the FDA, and no dose adjustment is needed when switching between injection areas. Your healthcare provider may recommend starting with the abdomen, as it tends to be the most comfortable site for self-injection, but all three locations are equally effective.

What is a good injection site rotation schedule?

A simple and effective approach is to rotate through the three body areas in a consistent pattern. For a weekly GLP-1 injection, a four-site rotation — right abdomen, left abdomen, right thigh, left thigh — covers one full month. You can extend this to a six-site cycle by adding the upper arms: right abdomen, left abdomen, right thigh, left thigh, right arm, left arm.

Within each body area, the Mounjaro prescribing information advises that you may use the same area of your body but should choose a different spot within that area each time. Healthcare professionals generally recommend spacing each injection point at least 1 inch (2.5 cm) from any previous site and avoiding any given spot for at least four weeks. This allows the tissue to fully recover between injections.

Here is an example of a simple six-week rotation cycle:

After week six, you return to the right abdomen and repeat the cycle. This ensures each area gets at least five weeks of rest between uses.

How do you track injection sites week to week?

The simplest method is keeping a written log — a notebook or calendar entry noting the date, body area, and side used for each injection. However, written logs are easy to forget or misplace, especially over months of weekly injections.

A dedicated tracking app can automate this process. Glone's injection-site tracking feature lets you log each injection location on a body map, view your rotation history at a glance, and see which site is next in your rotation. This takes the guesswork out of remembering where you injected two, three, or six weeks ago — which becomes increasingly difficult the longer you're on treatment.

Whichever method you choose, the key is consistency. Research on injection technique in diabetes care has shown that patients who follow a structured rotation plan have significantly fewer injection-site complications than those who inject by habit or convenience.

What happens if you inject in the same spot too often?

Repeated injections in the same area can lead to several problems. The most immediate is increased discomfort — overused tissue becomes tender, and injections may sting or bruise more easily. Over time, the tissue can develop lipohypertrophy, which feels like a rubbery lump under the skin.

The more serious concern is inconsistent medication absorption. When you inject into damaged or thickened tissue, the medication may be absorbed more slowly or incompletely. In insulin therapy, injecting into lipohypertrophic tissue has been associated with unexplained blood sugar fluctuations. For GLP-1 medications, this could mean inconsistent appetite suppression or variable side effects from week to week.

If you notice any lumps, hard areas, or persistent redness at an injection site, avoid that area and bring it to your healthcare provider's attention. Lipohypertrophic tissue can take weeks to months to resolve once you stop injecting into it.

Does the injection site affect how well the medication works?

For practical purposes, no. While pharmacokinetic studies have detected small differences in absorption between the abdomen, thigh, and upper arm, these differences do not require dose adjustments and are not considered clinically meaningful by regulatory agencies. The FDA prescribing information for both semaglutide and tirzepatide states that the medication can be injected in any of the three approved sites without changing the dose.

What does affect medication performance is injection technique. Injecting too shallowly (intradermally) or too deeply (intramuscularly) can alter absorption. GLP-1 pens are designed for subcutaneous injection — the needle should go straight into a pinch of skin at a 90-degree angle. If you are very lean, your healthcare provider may recommend a 45-degree angle to ensure the medication reaches the subcutaneous fat layer rather than the muscle beneath it.

Can you inject GLP-1 medications and insulin in the same area?

If you take both a GLP-1 medication and insulin, the Mounjaro prescribing information states that it is acceptable to inject both medications in the same body region — for example, both in the abdomen — as long as the injection sites are not adjacent to each other. The two medications should always be administered as separate injections and should never be mixed in the same syringe or pen.

A practical approach is to use one body area for your GLP-1 injection and a different area for insulin. For example, you might use the abdomen for your weekly GLP-1 injection and the thighs for daily insulin. This simplifies your rotation schedule and reduces the risk of accidentally injecting both medications into the same tissue.

What are some tips for more comfortable injections?

Several evidence-based techniques can reduce injection discomfort. Allow the medication to reach room temperature before injecting — cold solution from the refrigerator can cause more stinging. The Ozempic and Mounjaro prescribing information both recommend letting the pen sit at room temperature for approximately 30 minutes before use.

Choose an area with adequate subcutaneous fat. The abdomen is often the most comfortable because it typically has a thicker fat layer. Avoid areas with scars, stretch marks, bruises, or moles. Insert the needle quickly and steadily — a slow push through the skin tends to cause more discomfort than a firm, swift motion.

After injecting, hold the pen in place for the time recommended in the Instructions for Use — typically 5 to 10 seconds — to ensure the full dose is delivered. Do not rub the injection site afterward, as this can increase bruising and irritation. If you experience persistent nausea or injection-site reactions, talk to your healthcare provider about whether adjusting your injection technique or site could help.

How does Glone help with injection site tracking?

Glone's smart rotation feature records each injection on an interactive body map, showing you exactly where you injected and when. It suggests the next site in your rotation pattern, sends weekly injection reminders, and keeps a complete history you can share with your healthcare provider. This is especially useful during the dose titration phase, when tracking both your injection sites and any side effects can help your provider make more informed decisions about your treatment plan.

Sources

• FDA Prescribing Information for Ozempic (semaglutide) injection — accessdata.fda.gov
• FDA Prescribing Information for Mounjaro (tirzepatide) injection — accessdata.fda.gov
• FDA Prescribing Information for Wegovy (semaglutide) injection — accessdata.fda.gov
• Lipohypertrophy and Insulin: An Update From the Diabetes Literature. Diabetes Technology & Therapeutics. 2023. — pmc.ncbi.nlm.nih.gov
• Risk factors for Lipohypertrophy in People With Insulin-Treated Diabetes: A Systematic Meta-Analysis. — pmc.ncbi.nlm.nih.gov
• Lipohypertrophy: Symptoms, Causes, Treatment & Prevention — Cleveland Clinic. — clevelandclinic.org